Search Results

You are looking at 11 - 20 of 193 items for :

  • "tamoxifen" x
  • Refine by Access: All x
Clear All
Full access

Jennifer A. Ligibel and Eric P. Winer

References 1 Group EBTC . Tamoxifen for early breast cancer: an overview of the randomized trials . Lancet 1998 ; 351 : 1451 – 1467 . 2 Report from the Breast Cancer Trials Committee SCTO, Edinburgh . Adjuvant tamoxifen

Full access

Robert W. Carlson, Elizabeth Brown, Harold J. Burstein, William J. Gradishar, Clifford A. Hudis, Charles Loprinzi, Eleftherios Paul Mamounas, Edith A. Perez, Kathleen Pritchard, Peter Ravdin, Abram Recht, George Somlo, Richard L. Theriault, Eric P. Winer, Antonio C. Wolff, and for the NCCN Adjuvant Therapy for Breast Cancer Task Force

predictive factors? Can certain subsets of premenopausal women with ER-positive tumors be adequately treated using tamoxifen and/or ovarian suppression and forego adjuvant chemotherapy? What is the optimal strategy for using aromatase inhibitors (AIs) in the

Full access

Therese B. Bevers

– 5687 . 2. Lamb CA Helguero LA Fabris V . Differential effects of raloxifene, tamoxifen and fulvestrant on a murine mammary carcinoma . Breast Cancer Res Treat 2003 ; 79 : 25 – 35 . 3. Sporn MB Dowsett SA Mershon J Bryant HU

Full access

Alyssa G. Rieber and Richard L. Theriault

carcinoma of the mamma: suggestions for a new method of treatment, with illustrative cases . Lancet 1896 ; 2 : 104 – 107 . 2 Fisher B Costantino JP Wickerham DL . Tamoxifen for prevention of breast cancer: report of the National Surgical

Full access

Robert W. Carlson, Susan Moench, Arti Hurria, Lodovico Balducci, Harold J. Burstein, Lori J. Goldstein, William J. Gradishar, Kevin S. Hughes, Mohammad Jahanzeb, Stuart M. Lichtman, Lawrence B. Marks, Joan S. McClure, Beryl McCormick, Lisle M. Nabell, Lori J. Pierce, Mary Lou Smith, Neal S. Topham, Tiffany A. Traina, John H. Ward, and Eric P. Winer

anthracyclines or trastuzumab; 21 – 23 kidney dysfunction and capecitabine; 16 preexisting neuropathy and taxanes; 24 history of thromboembolism and tamoxifen (venous thromboembolism) or bevacizumab (arterial thromboembolism); 25 , 26 and osteoporosis and

Full access

Arvind Bambhroliya, Mariana Chavez-MacGregor, and Abenaa M. Brewster

). BCPT randomized women to receive tamoxifen or placebo, and results showed that the tamoxifen arm had a significant reduction in the risk of developing an estrogen receptor (ER)–positive tumor (relative risk [RR], 0.38; 95% CI, 0.28–0.50), and had no

Full access

Mandy R. Sakamoto, Megan Eguchi, Christine M. Azelby, Jennifer R. Diamond, Christine M. Fisher, Virginia F. Borges, Cathy J. Bradley, and Peter Kabos

). Patients who received tamoxifen or with depression/anxiety were more likely to develop persistent benzodiazepine use at 3 months (OR, 1.93 [95% CI, 1.12–3.33] and 1.74 [CI, 1.01–3.01], respectively). The other subgroup consisted primarily of clonazepam and

Full access

Julie R. Gralow, J. Sybil Biermann, Azeez Farooki, Monica N. Fornier, Robert F. Gagel, Rashmi Kumar, Georgia Litsas, Rana McKay, Donald A. Podoloff, Sandy Srinivas, and Catherine H. Van Poznak

, United Kingdom: Blackwell Healthcare Communications; 1997:22–55. b Eastell R, Hannon RA, Cuzick J, et al. Effect of anastrozole on bone density and bone turnover: results of the ‘Arimidex’ (anastrozole), Tamoxifen, Alone or in Combination (ATAC) study

Full access

William Gradishar and Kilian E. Salerno

recent trial data. For premenopausal women at diagnosis, the NCCN Guidelines for Breast Cancer suggest tamoxifen for 5 years, with or without ovarian suppression, or an AI for 5 years combined with ovarian suppression or ablation (category 1). Women who

Full access

John A. Charlson, Emily L. McGinley, Ann B. Nattinger, Joan M. Neuner, and Liliana E. Pezzin

studying the relationship between pharmaceutical plan characteristics and choice of therapy. For most postmenopausal women with hormone receptor–positive (HR+) disease there are essentially 2 options for oral endocrine therapy: tamoxifen, whose efficacy was